A Phase 3 interventional study of Ranibizumab and Laser photocoagulation in Diabetic Macular Edema, sponsored by Novartis. Completed at 35 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-10-18.
Sponsored by Novartis · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies testing ranibizumab in Edema — none open to participants now, none under way, none of them phase 3. Ranibizumab · Edema.
Among the 13 studies testing ranibizumab in Edema, this one is the 2nd largest by enrollment, is the only one that started in 2009, is one of 5 in phase 3, and was the 5th registered.
568 studies on the registry are indexed under Edema; 97 are open to participants now.
Browse Edema studies →None of the 13 studies testing ranibizumab in Edema is open now. The open studies under Edema, anywhere →
Ranibizumab: first FDA approval 2006 (LUCENTIS), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 56 Edema studies recruiting now, 34 (61%) set no upper age limit and 16 (29%) stop at 75 or younger; 8 take children under 18; 4 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 4 · Phase 3 5 · Phase 4 3
First in 2007; this study’s year is marked. 1 started in 2009.
This study's enrollment of 396 is above the median of 54 across 402 interventional studies indexed under Edema.
Median enrollment 50 across the 13 interventional studies. Of the 11 that completed or were terminated, 6 (55%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 13 have an industry lead sponsor. The 10 most frequent:
Novartis is the lead sponsor of 714 studies on the registry; none are open to participants now.
Novartis has 4 studies filed under Edema — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 13 studies testing ranibizumab in Edema, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study was designed to confirm the efficacy and safety of ranibizumab (0.5 mg) as adjunctive therapy when added to laser photocoagulation and/or as monotherapy in Asian patients with visual impairment due to Diabetic Macular Edema (DME).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
The study eye must fulfill the following criteria at Visit 1:
Exclusion Criteria:
Ocular concomitant conditions/ diseases:
Ocular treatments:
Systemic conditions or treatments:
Compliance/ Administrative:
Other protocol-defined inclusion/exclusion criteria may apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjunctive administration of ranibizumab 0.5 mg intravitreal injections and active laser.
Drug: Ranibizumab · Procedure: Laser photocoagulation
Monotherapy ranibizumab 0.5 mg intravitreal injections plus sham laser.
Drug: Ranibizumab · Procedure: Sham laser photocoagulation
Active laser treatment plus sham intravitreal injections.
Procedure: Laser photocoagulation · Drug: Sham ranibizumab
Ranibizumab 0.5 mg intravitreal injection at day 1, month 1 and month 2. If stable vision not reached at month 3, one injection per month continued until stable vision was reached. Intravitreal injections re-initiated if needed.
Active laser treatment administered at day 1. Subsequent laser treatments administered if needed at intervals no shorter than 3 months from previous laser treatment.
Sham intravitreal injections to ranibizumab at day 1, month 1 and month 2. Intravitreal injections re-initiated if needed.
Sham laser treatment administered at day 1.
Average Change From Baseline of Best-Corrected Visual Acuity (BCVA) Over 12 Months (From Month 1 to Month 12 Compared to Baseline)
Best-Corrected Visual Acuity (BCVA) letters was measured using Early Treatment Diabetic Retinopathy Study (EDTRS)-like chart while participants were in a sitting position at a testing distance of 4 meters. The range of EDTRS is 0 to 100 letters. A positive average change from baseline of BCVA indicates improvement.
Time frame: 12 months
Change From Baseline on Central Retinal Subfield Thickness (CRST) at Month 12
Central Retinal Subfield Thickness (CRST) was measured using Optical Coherence Tomography (OCT) in micrometers. A negative change from baseline of CRST indicates improvement.
Time frame: 12 months
Percent of Participants With Anatomical Changes in Intra-retinal Cysts at End of Study Compared to Baseline
Presence or absence of intra-retinal cysts in any of the 6 sections of the study eye was measured using Optical Coherence Tomography (OCT). A complete resolution or decrease from baseline of intra-retinal cysts indicates improvement.
Time frame: Up to 12 months
Percent of Participants With Anatomical Changes in Sub-retinal Fluid at End of Study Compared to Baseline
Presence or absence of sub-retinal fluid in any of the 6 sections of the study eye was measured using Optical Coherence Tomography (OCT). A complete resolution or decrease from baseline of sub-retinal fluid indicates improvement.
Time frame: Up to 12 months
Percent of Participants With Visual Acuity Above 73 Letters at Month 12
Best Corrected Visual Acuity (BCVA) was measured using Early Treatment Diabetic Retinopathy Study (ETDRS)-like chart at baseline and month 12 while participants were in a sitting position at a testing distance of 4 meters. The range of EDTRS is 0 to 100 letters. BCVA above 73 letters at month 12 indicates a positive outcome.
Time frame: 12 months
Percent of Participants Who Gained >= 10 Letters at Month 12 Compared to Baseline
Best-Corrected Visual Acuity (BCVA) letters was measured using Early Treatment Diabetic Retinopathy Study (EDTRS)-like chart while participants were in a sitting position at a testing distance of 4 meters. The range of EDTRS is 0 to 100 letters. A gain of 10 or more BCVA letters from baseline indicates improvement. A BCVA of 84 letters or more at Month 12 indicates improvement.
Time frame: 12 months
Percent of Participants Who Lost >= 10 Letters at Month 12 Compared to Baseline
Best-Corrected Visual Acuity (BCVA) letters was measured using Early Treatment Diabetic Retinopathy Study (EDTRS)-like chart while participants were in a sitting position at a testing distance of 4 meters. The range of EDTRS is 0 to 100 letters. A loss of 10 or more BCVA letters from baseline indicates worsening.
Time frame: 12 months
Percent of Participants Who Gained >= 15 Letters at Month 12 Compared to Baseline
Best-Corrected Visual Acuity (BCVA) letters was measured using Early Treatment Diabetic Retinopathy Study (EDTRS)-like chart while participants were in a sitting position at a testing distance of 4 meters. The range of EDTRS is 0 to 100 letters. A gain of 15 or more BCVA letters from baseline indicates improvement. A BCVA of 84 letters or more at Month 12 indicates improvement.
Time frame: 12 months
Percent of Participants Who Lost >= 15 Letters at Month 12 Compared to Baseline
Best-Corrected Visual Acuity (BCVA) letters was measured using Early Treatment Diabetic Retinopathy Study (EDTRS)-like chart while participants were in a sitting position at a testing distance of 4 meters. The range of EDTRS is 0 to 100 letters. A loss of 15 or more BCVA letters from baseline indicates worsening.
Time frame: 12 months
Best-Corrected Visual Acuity (BCVA) Mean Change From Baseline at Month 12
Best-Corrected Visual Acuity (BCVA) letters was measured using Early Treatment Diabetic Retinopathy Study (EDTRS)-like chart while participants were in a sitting position at a testing distance of 4 meters. The range of EDTRS is 0 to 100 letters. A positive change from baseline of BCVA indicates improvement.
Time frame: 12 months
Patient Outcome Measure Euro Quality of Life Questionnaire (EQ-5D)
The Euro Quality of Life Questionnaire (EQ-5D) standardized instrument was utilized to measure health outcomes related to mobility, self care, usual activities, pain/discomfort, and anxiety/depression. Participants self-rate their health on a visual, vertical analogue scale from 0 to 100 where the endpoints are labeled "Best imaginable health state" (100) and "worst imaginable health state" (0).
Time frame: 12 months
| Milestone | Adjunctive Treatment | Monotherapy Treatment | Laser Control |
|---|---|---|---|
| Started | 132 | 133 | 131 |
| Completed | 114 | 123 | 108 |
| Not completed | 18 | 10 | 23 |
Best-Corrected Visual Acuity (BCVA) letters was measured using Early Treatment Diabetic Retinopathy Study (EDTRS)-like chart while participants were in a sitting position at a testing distance of 4 meters. The range of EDTRS is 0 to 100 letters. A positive average change from baseline of BCVA indicates improvement.
| Letters | Adjunctive Treatment | Monotherapy Treatment | Laser Control |
|---|---|---|---|
| Average Change From Baseline of Best-Corrected Visual Acuity (BCVA) Over 12 Months (From Month 1 to Month 12 Compared to Baseline) | 5.7 ± 7.20 | 5.9 ± 6.02 | 1.4 ± 6.49 |
Central Retinal Subfield Thickness (CRST) was measured using Optical Coherence Tomography (OCT) in micrometers. A negative change from baseline of CRST indicates improvement.
| micrometers | Adjunctive Treatment | Monotherapy Treatment | Laser Control |
|---|---|---|---|
| Change From Baseline on Central Retinal Subfield Thickness (CRST) at Month 12 | -171.8 ± 160.85 | -134.6 ± 131.17 | -57.2 ± 118.60 |
Presence or absence of intra-retinal cysts in any of the 6 sections of the study eye was measured using Optical Coherence Tomography (OCT). A complete resolution or decrease from baseline of intra-retinal cysts indicates improvement.
| percentage of participants | Adjunctive Treatment | Monotherapy Treatment | Laser Control |
|---|---|---|---|
| complete resolution | 19.5 | 21.8 | 6.5 |
| decrease | 40.3 | 42.3 | 35.1 |
| no change | 5.2 | 5.1 | 15.6 |
| increase | 1.3 | 1.3 | 10.4 |
| not applicable | 2.6 | 1.3 | 0 |
| missing | 31.2 | 28.2 | 32.5 |
Presence or absence of sub-retinal fluid in any of the 6 sections of the study eye was measured using Optical Coherence Tomography (OCT). A complete resolution or decrease from baseline of sub-retinal fluid indicates improvement.
| percentage of participants | Adjunctive Treatment | Monotherapy Treatment | Laser Control |
|---|---|---|---|
| complete resolution | 13.6 | 33.3 | 25.0 |
| decrease | 18.2 | 11.1 | 18.8 |
| no change | 4.5 | 0 | 6.3 |
| increase | 0 | 0 | 0 |
| not applicable | 31.8 | 18.5 | 12.5 |
| missing | 31.8 | 37.0 | 37.5 |
Best Corrected Visual Acuity (BCVA) was measured using Early Treatment Diabetic Retinopathy Study (ETDRS)-like chart at baseline and month 12 while participants were in a sitting position at a testing distance of 4 meters. The range of EDTRS is 0 to 100 letters. BCVA above 73 letters at month 12 indicates a positive outcome.
| percentage of participants | Adjunctive Treatment | Monotherapy Treatment | Laser Control |
|---|---|---|---|
| Percent of Participants With Visual Acuity Above 73 Letters at Month 12 | 20.5 | 16.5 | 8.5 |
Best-Corrected Visual Acuity (BCVA) letters was measured using Early Treatment Diabetic Retinopathy Study (EDTRS)-like chart while participants were in a sitting position at a testing distance of 4 meters. The range of EDTRS is 0 to 100 letters. A gain of 10 or more BCVA letters from baseline indicates improvement. A BCVA of 84 letters or more at Month 12 indicates improvement.
| Percentage of participants | Adjunctive Treatment | Monotherapy Treatment | Laser Control |
|---|---|---|---|
| Percent of Participants Who Gained >= 10 Letters at Month 12 Compared to Baseline | 37.2 ± 37.2 | 33.8 ± 33.8 | 13.3 ± 13.3 |
Best-Corrected Visual Acuity (BCVA) letters was measured using Early Treatment Diabetic Retinopathy Study (EDTRS)-like chart while participants were in a sitting position at a testing distance of 4 meters. The range of EDTRS is 0 to 100 letters. A loss of 10 or more BCVA letters from baseline indicates worsening.
| Percentage of participants | Adjunctive Treatment | Monotherapy Treatment | Laser Control |
|---|---|---|---|
| Percent of Participants Who Lost >= 10 Letters at Month 12 Compared to Baseline | 5.4 | 3.0 | 6.3 |
Best-Corrected Visual Acuity (BCVA) letters was measured using Early Treatment Diabetic Retinopathy Study (EDTRS)-like chart while participants were in a sitting position at a testing distance of 4 meters. The range of EDTRS is 0 to 100 letters. A gain of 15 or more BCVA letters from baseline indicates improvement. A BCVA of 84 letters or more at Month 12 indicates improvement.
| Percentage of participants | Adjunctive Treatment | Monotherapy Treatment | Laser Control |
|---|---|---|---|
| Percent of Participants Who Gained >= 15 Letters at Month 12 Compared to Baseline | 17.8 | 18.8 | 7.8 |
Best-Corrected Visual Acuity (BCVA) letters was measured using Early Treatment Diabetic Retinopathy Study (EDTRS)-like chart while participants were in a sitting position at a testing distance of 4 meters. The range of EDTRS is 0 to 100 letters. A loss of 15 or more BCVA letters from baseline indicates worsening.
| Percentage of participants | Adjunctive Treatment | Monotherapy Treatment | Laser Control |
|---|---|---|---|
| Percent of Participants Who Lost >= 15 Letters at Month 12 Compared to Baseline | 3.9 | 1.5 | 3.9 |
Best-Corrected Visual Acuity (BCVA) letters was measured using Early Treatment Diabetic Retinopathy Study (EDTRS)-like chart while participants were in a sitting position at a testing distance of 4 meters. The range of EDTRS is 0 to 100 letters. A positive change from baseline of BCVA indicates improvement.
| Letters | Adjunctive Treatment | Monotherapy Treatment | Laser Control |
|---|---|---|---|
| Best-Corrected Visual Acuity (BCVA) Mean Change From Baseline at Month 12 | 6.4 ± 10.67 | 6.6 ± 7.68 | 1.8 ± 8.27 |
The Euro Quality of Life Questionnaire (EQ-5D) standardized instrument was utilized to measure health outcomes related to mobility, self care, usual activities, pain/discomfort, and anxiety/depression. Participants self-rate their health on a visual, vertical analogue scale from 0 to 100 where the endpoints are labeled "Best imaginable health state" (100) and "worst imaginable health state" (0).
| units on a scale | Adjunctive Treatment | Monotherapy Treatment | Laser Control |
|---|---|---|---|
| Patient Outcome Measure Euro Quality of Life Questionnaire (EQ-5D) | 2.8 ± 14.38 | -1.1 ± 12.74 | 1.0 ± 13.90 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Monotherapy Treatment | — | 21/133 (15.8%) | 36/133 (27.1%) |
| Adjunctive Treatment | — | 22/132 (16.7%) | 36/132 (27.3%) |
| Laser Control | — | 19/128 (14.8%) | 23/128 (18%) |
| Event | Monotherapy Treatment | Adjunctive Treatment | Laser Control |
|---|---|---|---|
| Lumbar spinal stenosisMusculoskeletal and connective tissue disorders | 0/133 | 0/132 | 2/128 |
| Cerebral infarctionNervous system disorders | 0/133 | 0/132 | 2/128 |
| Cardiac failure chronicCardiac disorders | 0/133 | 2/132 | 0/128 |
| Cataract (Fellow eye)Eye disorders | 1/133 | 2/132 | 0/128 |
| Cataract (Study eye)Eye disorders | 0/133 | 2/132 | 0/128 |
| Endophthalmitis (Study eye)Infections and infestations | 1/133 | 2/132 | 0/128 |
| Angina pectorisCardiac disorders | 2/133 | 0/132 | 1/128 |
| Maculopathy (Fellow eye)Eye disorders | 2/133 | 0/132 | 0/128 |
| Vitreous haemorrhage (Fellow eye)Eye disorders | 2/133 | 0/132 | 1/128 |
| Traumatic intracranial haemorrhageInjury, poisoning and procedural complications | 2/133 | 0/132 | 0/128 |
| Event | Monotherapy Treatment | Adjunctive Treatment | Laser Control |
|---|---|---|---|
| Conjunctival haemorrhage (Study eye)Eye disorders | 17/133 | 12/132 | 7/128 |
| Diabetic retinal oedema (Fellow eye)Eye disorders | 11/133 | 8/132 | 2/128 |
| NasopharyngitisInfections and infestations | 10/133 | 10/132 | 8/128 |
| HypertensionVascular disorders | 6/133 | 7/132 | 6/128 |
| Age Continuous(years) | Adjunctive Treatment | Monotherapy Treatment | Laser Control | Total |
|---|---|---|---|---|
| Mean | 61.2 ± 10.52 | 60.7 ± 9.37 | 61.5 ± 9.68 | 61.1 ± 9.85 |
| Sex: Female, Male(Participants) | Adjunctive Treatment | Monotherapy Treatment | Laser Control | Total |
|---|---|---|---|---|
| Female | 65 | 52 | 56 | 173 |
| Male | 67 | 81 | 75 | 223 |
The record gives a start of Sep 2009, a primary completion of Aug 2011 and a completion of Aug 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2012, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ranibizumab